- Integra LifeSciences (NASDAQ:IART) expects Q3 revenue to be in range of $368-$370M indicating a Y/Y decline of ~2.7% on a reported basis and ~1.8% on an organic basis.
- Q3 sales improvement was broad-based across the company’s major franchises.
- The results exceed the company's Q3 revenue outlook range provided in August.
- Q3 results scheduled for Oct. 28, 2020, before market opens.
- https://seekingalpha.com/news/3620263-integra-lifesciences-indicates-q3-prelim-revenue
Tuesday, October 6, 2020
Integra LifeSciences has Q3 prelim revenue
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.